Overview

Clinical trials and clinical research are crucial for advancing medical knowledge, improving patient care, and developing new treatments and therapies. Achieving success in this field requires collaboration, innovation, and strategic decision-making.

Agilisium will be at Scope Summit 2025 in Orlando, Florida, from February 3–6. This premier event will bring together 4,000+ attendees and 1,200 organizations from 30 countries to explore the future of clinical trials, digital health, and patient care.

We invite you to connect with our experts, experience live demos, and discover how Agilisium’s cutting-edge solutions can optimize clinical operations, enhance patient engagement, and drive successful clinical trial outcomes.

No items found.
Meet Our Team of Experts at Scope Summit 2025

Connect with our life science experts at SCOPE Summit 2025 to learn how our Next-Gen AI agents are helping our customers optimize their clinical operations and trials.

Arun Kumar
Chief Technology Officer
Arvind Ramakrishnan
Senior Vice President – Life Sciences, North America
Rahul Venkat
Associate Director - Client Services, Life Sciences
Book a Meeting

Industry Recognition

Featured Reports

Agilisium Recognized as a Leader in Everest Group Life Sciences Digital Services for Mid-Market Enterprises PEAK Matrix® Report.

The Everest Group evaluated Agilisium’s capabilities across the Life Sciences value chain along with client case studies and references.

Agilisium Recognized as a Product Challenger in ISG Provider Lens™ Life Sciences and Healthcare Analytics Services — Specialist Providers 2024 study.

The ISG Group evaluated Agilisium’s  expertise in enabling enterprises to improve decision-making utilizing AI and analytics.

Agilisium Recognized as a Product Challenger in ISG Provider Lens™ AWS Ecosystem Partners — Data Analytics, AI and ML Providers 2023 study.

The ISG Group evaluated Agilisium’s  ability to utilize analytics and ML to convert data into insights, driving innovation and efficiency in client operations.